180 related articles for article (PubMed ID: 26560244)
1. Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression.
Schaefer-Klein JL; Murphy SJ; Johnson SH; Vasmatzis G; Kovtun IV
PLoS One; 2015; 10(11):e0142327. PubMed ID: 26560244
[TBL] [Abstract][Full Text] [Related]
2. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract][Full Text] [Related]
3. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
[TBL] [Abstract][Full Text] [Related]
5. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
6. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
7. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
9. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
10. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
12. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
14. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
[TBL] [Abstract][Full Text] [Related]
15. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
[No Abstract] [Full Text] [Related]
16. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
Zolochevska O; Figueiredo ML
Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha.
Hua W; Sa KD; Zhang X; Jia LT; Zhao J; Yang AG; Zhang R; Fan J; Bian K
Biochem Biophys Res Commun; 2015 Aug; 463(4):1077-83. PubMed ID: 26079880
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival.
Murata T; Takayama K; Urano T; Fujimura T; Ashikari D; Obinata D; Horie-Inoue K; Takahashi S; Ouchi Y; Homma Y; Inoue S
Clin Cancer Res; 2012 Oct; 18(20):5617-27. PubMed ID: 22904106
[TBL] [Abstract][Full Text] [Related]
19. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
Margiotti K; Wafa LA; Cheng H; Novelli G; Nelson CC; Rennie PS
Mol Cancer; 2007 Jun; 6():38. PubMed ID: 17553164
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth.
Mygatt JG; Singhal A; Sukumar G; Dalgard CL; Kaleeba JA
Cancer Res; 2013 Sep; 73(18):5695-708. PubMed ID: 24005834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]